{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:27:54Z","timestamp":1766186874836,"version":"3.48.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.abd.2025.501239","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:00:58Z","timestamp":1761984058000},"page":"501239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of tralokinumab in a patient with severe atopic dermatitis and hepatitis B virus"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0073-4039","authenticated-orcid":false,"given":"Mar\u00eda","family":"Olivares-Guerrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1665-1822","authenticated-orcid":false,"given":"Ana","family":"Jim\u00e9nez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Aparicio-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-4262","authenticated-orcid":false,"given":"Pablo","family":"Chicharro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501239_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.abd.2025.501239_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"10.1016\/j.abd.2025.501239_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501239_bib0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2025.501239_bib0025","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/jdv.18922","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2025.501239_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.abd.2025.501239_bib0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jdcr.2019.05.007","article-title":"Dupilumab in patients with chronic hepatitis B on concomitant entecavir","volume":"5","author":"Ly","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.abd.2025.501239_bib0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cia2.12209","article-title":"Dupilumab in atopic dermatitis patients with chronic hepatitis B","volume":"5","author":"Matsutani","year":"2022","journal-title":"J Cutan Immunol Allergy"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:24:49Z","timestamp":1766186689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0365059625001813"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501239","relation":{},"ISSN":["0365-0596"],"issn-type":[{"type":"print","value":"0365-0596"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of tralokinumab in a patient with severe atopic dermatitis and hepatitis B virus","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501239"}}